COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
COLLEGIUM PHARMACEUTICAL, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$23.01−0.18 (-0.78%)
Close on Oct 19, 2026
- Market cap
- $746.92M
- P/E (TTM)
- 18.6
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Gross margin
59.3%+1.3 pts over 5 years
Operating margin
23.0%+4.9 pts over 5 years
Net margin
8.1%−0.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +23.6% | +18.9% | +20.3% | – | |
| Gross profit | +22.8% | +30.3% | +20.8% | – | |
| Operating income | +5.7% | +75.3% | +26.1% | – | |
| Net income | -9.1% | – | +18.6% | – | |
| EPS, diluted | -7.0% | – | +17.9% | – | |
| Free cash flow | +61.1% | +38.8% | +30.0% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -85.6% | 19.6% | 23.7% | |
| Return on assets | -72.5% | 5.6% | 3.8% | |
| Current ratio | 6.20 | 1.16 | 1.57 | |
| Interest coverage | -1000.9× | 1.9× | 2.2× | |
| Inventory turnover | – | 10.3× | 8.3× | |
| Capex to revenue | 27.9% | 1.8% | 0.2% | |
| Diluted shares | 24M | 35M | 40M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Collegium Pharmaceutical generated $1.04B from operations and spent $229.47M on capital expenditure, dividends and share buybacks. 3% of that went back into the business.
Generated
$1.04B
Used
$229.47M
Capital expenditure$7.42M3%Dividends$00%Share buybacks$222.05M97%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin8.1%
×Asset turnover0.47×
×Equity multiplier6.26×
=Return on equity, FY202523.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 8.1% | 0.47× | 6.26× | 23.7% |
| FY2024 | 11.0% | 0.45× | 6.62× | 32.6% |
| FY2023 | 8.5% | 0.49× | 5.94× | 24.7% |
| FY2022 | -5.4% | 0.50× | 4.69× | -12.6% |
| FY2021 | 25.8% | 0.41× | 3.43× | 36.8% |
| FY2020 | 8.6% | 0.65× | 3.47× | 19.6% |
| FY2019 | -7.7% | 0.99× | 3.34× | -25.4% |
| FY2018 | -14.0% | 1.31× | 2.18× | -40.0% |
| FY2017 | -262.9% | 0.19× | 1.25× | -62.7% |
| FY2016 | -5504.1% | 0.01× | 1.18× | -85.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$62.87M
- Cash generatingOperating cash flow above zero$329.32M
- Return on assets improvedROA up on the prior year6.1% → 3.8%
- Earnings backed by cashOperating cash flow above net income$329.32M vs $62.87M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.95 → 1.57
- No dilutionShare count did not rise40M → 40M
- Gross margin improvedGross margin up on the prior year59.76% → 59.35%
- More efficientAsset turnover rose0.55 → 0.47